Sarepta Therapeutics, Inc.SRPTNASDAQ
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 7.09% |
| Q2 2025 | -73.57% |
| Q1 2025 | 286.81% |
| Q4 2024 | -10.93% |
| Q3 2024 | 24.93% |
| Q2 2024 | -10.33% |
| Q1 2024 | 2.50% |
| Q4 2023 | 0.63% |
| Q3 2023 | -19.67% |
| Q2 2023 | -1.54% |
| Q1 2023 | 14.91% |
| Q4 2022 | -1.34% |
| Q3 2022 | -14.12% |
| Q2 2022 | 29.90% |
| Q1 2022 | -1.54% |
| Q4 2021 | 41.82% |
| Q3 2021 | -41.94% |
| Q2 2021 | 22.79% |
| Q1 2021 | -5.83% |
| Q4 2020 | 8.82% |
| Q3 2020 | 1.02% |
| Q2 2020 | 38.47% |
| Q1 2020 | -38.99% |
| Q4 2019 | 66.59% |
| Q3 2019 | 18.26% |
| Q2 2019 | 25.08% |
| Q1 2019 | -38.07% |
| Q4 2018 | 68.86% |
| Q3 2018 | -29.52% |
| Q2 2018 | 165.88% |
| Q1 2018 | 3.97% |
| Q4 2017 | 29.80% |
| Q3 2017 | -41.88% |
| Q2 2017 | 102.30% |
| Q1 2017 | -58.84% |
| Q4 2016 | 105.97% |
| Q3 2016 | -22.55% |
| Q2 2016 | 14.22% |
| Q1 2016 | -6.16% |
| Q4 2015 | 12.82% |